Will the FDA approve camizestrant for advanced breast cancer?

1.0 ptn (24u)Health & MedicineOne-Off2mnd

KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensGrof gekalibreerd

Huidige impliciete kans

Before Jan 1, 2028 77%

Koploper van 5 uitkomsten

Marktkwaliteit

45 / 100

Lage kwaliteit

24u volume

€ 47

Liquiditeit

€ 3,9K

Gemiddelde liquiditeit

Bied / Laat

32.0% / 37.0%

Spread

5.0 pt

Gematigde spread

Marktdata

Bijgewerkt 13 minuten geleden

14 mei 26, 2:001 okt 26, 3:59

Trends

Uitkomst24uKans

Alleen virtueel geld, geen echt geldGeen financieel advies

Gekozen uitkomst

Before Oct 1, 202637%

Inzet (USDT)

Regels

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Volumetrend

$53

2 jul14d aan data28 jul

Gerelateerde Markten

Will the FDA approve MDMA for PTSD?

€ 0

Before Jan 1, 2027: 10%

KALSHI

Hantavirus pandemic in 2026?

€ 97,7K

Ja: 3%

POLYMARKET

# of views of MrBeast video day 3?

€ 6,5K

26-27M: 73%

POLYMARKET

New pandemic in 2026?

€ 5,2K

Ja: 9%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Actief in deze onderwerpen

BitcoinBTC$63,512.42-3.08%

EthereumETH$1,882.58-4.26%

SolanaSOL$73.37-4.37%

DogecoinDOGE$0.0701-4.22%

XRPXRP$1.06-4.80%

BNBBNB$565.25-1.65%

Gerelateerd Nieuws

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regels

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Will the FDA approve camizestrant for advanced breast cancer?

1.0 ptn (24u)Health & MedicineOne-Off2mnd

KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensGrof gekalibreerd

Huidige impliciete kans

Before Jan 1, 2028 77%

Koploper van 5 uitkomsten

Marktkwaliteit

45 / 100

Lage kwaliteit

24u volume

€ 47

Liquiditeit

€ 3,9K

Gemiddelde liquiditeit

Bied / Laat

32.0% / 37.0%

Spread

5.0 pt

Gematigde spread

Marktdata

Bijgewerkt 13 minuten geleden

14 mei 26, 2:001 okt 26, 3:59

Trends

Uitkomst24uKans

Alleen virtueel geld, geen echt geldGeen financieel advies

Gekozen uitkomst

Before Oct 1, 202637%

Inzet (USDT)

Regels

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Volumetrend

$53

2 jul14d aan data28 jul

Gerelateerde Markten

Will the FDA approve MDMA for PTSD?

€ 0

Before Jan 1, 2027: 10%

KALSHI

Hantavirus pandemic in 2026?

€ 97,7K

Ja: 3%

POLYMARKET

# of views of MrBeast video day 3?

€ 6,5K

26-27M: 73%

POLYMARKET

New pandemic in 2026?

€ 5,2K

Ja: 9%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Actief in deze onderwerpen

BitcoinBTC$63,512.42-3.08%

EthereumETH$1,882.58-4.26%

SolanaSOL$73.37-4.37%

DogecoinDOGE$0.0701-4.22%

XRPXRP$1.06-4.80%

BNBBNB$565.25-1.65%

Gerelateerd Nieuws

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regels

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals: